HAEMALOGIX
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System Therapeutics Ltd and is embarking on a program of several inter-related projects that will validate antigen targets and products. Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific... to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia. Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include: validation of antibodies and CAR-T cells; proof of concept for both Kappa and Lambda antigens; and a good understanding of their clinical utility in treating the selected patient populations In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.
HAEMALOGIX
Industry:
Biotechnology Health Care Life Science Medical
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.haemalogix.com
Total Employee:
1+
Status:
Active
Contact:
+61292094444
Total Funding:
10 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online GStatic Google Static Content Sectigo SSL Sectigo Domain SSL
Similar Organizations
Arctic Vision
Arctic Vision is focused on the development and commercialization of innovative ophthalmology therapies.
iRepertoire
iRepertoire is to develop and commercialize immune repertoire sequencing technology and products.
myNEO
myNEO engages in the research, development, and optimization of the clinical exploitability of personalized cancer immunotherapy.
MYOR
MYOR uses skin-surface noninvasive monitoring technologies to adjust nutrition and enable health.
Pharmaceutical Biotechnology
Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.
Proteona
Proteona develops a genomic and proteomic analysis platform designed for immuno-oncology and immune profiling applications.
Reset Pharmaceuticals
Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments.
ScalmiBio
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Current Employees Featured
Alan Liddle Co-Founder & Board Member @ Haemalogix
Co-Founder & Board Member
Bryce Carmine Co-Founder, Chairman & CEO @ Haemalogix
Co-Founder, Chairman & CEO
2015-03-01
Dimitra Korkidas CFO @ Haemalogix
CFO
2015-03-01
Professor Mohamad Hussein Chief Medical Advisor @ Haemalogix
Chief Medical Advisor
Founder
Investors List
Platinum Asset Management
Platinum Asset Management investment in Venture Round - Haemalogix
Official Site Inspections
http://www.haemalogix.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Haemalogix"
Team - Haemalogix
HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development efforts to treat multiple myeloma. Multiple myeloma …See details»
Haemalogix - Crunchbase Company Profile & Funding
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System …See details»
Org Chart HaemaLogiX - The Official Board
Organizational Chart of HaemaLogiX. HaemaLogiX haemalogix.com. has 11 executives +61 292 094 444; Add an executive. HaemaLogiX News . Anything missing? We search for you. Print …See details»
HaemaLogiX Company Profile | Management and Employees List
HaemaLogiX Profile and History. Founded in 2014, HaemaLogiX Pty Ltd is a clinical stage biotech developing novel immuno-oncology and immune therapies for patients with blood cancers. …See details»
Contact | HaemaLogiX
HaemaLogiX Ltd. Suite 306, Level 3, 343 George Street SYDNEY NSW 2000. Australia. Contact Us. HaemaLogiX Ltd. Suite 306, Level 3, 343 George Street SYDNEY NSW 2000. Australia. …See details»
HaemaLogiX Company Profile 2024: Valuation, Funding
HaemaLogiX General Information Description. Developer of novel immuno-oncology and immune therapies intended for treating hematologic malignancies and auto-immune diseases. The …See details»
HaemaLogiX Ltd Overview | SignalHire Company Profile
HaemaLogiX Ltd is a private company. The company currently specializes in the Biotechnology area. Its headquarters is located at Nova Scotia, CA ... Organization Website: haemalogix.com …See details»
Haemalogix's Leadership Team - Team members and org chart
Other teams at Haemalogix. View all +5. Board of Directors. 8 members +1. CEO and Executive Team. 4 members. The Org helps you hire great candidates. It takes less than ten minutes to …See details»
Haemalogix - Contacts, Employees, Board Members, Advisors
Haemalogix has 5 current employee profiles, including Co-Founder & Board Member Alan Liddle. Alan Liddle Co-Founder & Board Member Damian Clarke-Bruce Managing Director & Chief …See details»
Haemalogix - Org Chart, Teams, Culture & Jobs - The Org
View Haemalogix's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Dr. John Cullity Appointed Chairman of HaemaLogiX
Jan 3, 2024 Dr. Cullity has been on the HaemaLogiX board since 2014 as a founding shareholder and brings 20+ years of industry and commercial markets experience. In addition …See details»
Haemalogix - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Dec 10, 2024 Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»
HaemaLogiX Pty Ltd. - Drug pipelines, Patents, Clinical trials
He will be invaluable in his continued role on the Board." About HaemaLogiX Ltd - : Formed in 2014, HaemaLogiX is a public unlisted biotech company researching antibody therapies for …See details»
HaemaLogiX Ltd - VentureRadar
HaemaLogiX is at the forefront of developing innovative immunotherapies for patients with blood cancers and B-cell disorders. Specializing in monoclonal antibodies, CAR-T cells, and …See details»
HaemaLogiX - Overview, News & Similar companies | ZoomInfo.com
Nov 14, 2023 HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director SYDNEY, May 20, 2024 …See details»
Haemalogix - Company Profile - Tracxn
Nov 7, 2024 Haemalogix ranks 157th among 492 active competitors. 186 of its competitors are funded while 117 have exited. Overall, Haemalogix and its competitors have raised over …See details»
Haemalogix - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 8, 2021: Venture Round - …See details»
Pipeline - Haemalogix
In July 2023, HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX’s CAR-T cell …See details»
Hologic Completes Acquisition of Gynesonics, Inc.
1 day ago Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical …See details»
Technology - Haemalogix
HaemaLogiX has discovered two antigens that are found on the cell surface of cancer cells in patients with myeloma and AL amyloidosis, on some lymphoma and Waldenstrom’s …See details»